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sequential procedures. Tests were performed at baseline 
and at 6 months. The primary endpoint was the improve-
ment from baseline in 6-min walking distance (6MWD) after 
treatment.  Results: Ten patients with severe airway obstruc-
tion and hyperinflation were treated. A median of 11 (range 
10–12) coils were placed in each lung. Two chronic obstruc-
tive pulmonary disease exacerbations and one small pneu-
mothorax were recorded as serious adverse events. At 
6 months, 6MWD had improved from 289 to 350 m (p = 
0.005); forced vital capacity from 2.17 to 2.55 liters (p = 0.047); 
residual volume from 5.04 to 4.44 liters (p = 0.007) and St. 
George’s Respiratory Questionnaire from 63 to 48 points (p = 
0.028).  Conclusion: LVR coil treatment in homogeneous pa-
tients improves hyperinflation, airway resistance, exercise 
capacity and quality of life with an acceptable safety profile. 
The benefit of LVR coil treatment is not limited to patients 
with heterogeneous emphysema, and patients with homog-
enous emphysema can benefit as well. 
 © 2014 S. Karger AG, Basel 
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 Abstract 
 Background: In patients with heterogeneous emphysema, 
surgical and  bronchoscopic lung volume reduction (LVR) 
treatments are available. However, for patients with homo-
geneous emphysema these treatments are hardly investi-
gated and seem less effective. Bronchoscopic LVR coil treat-
ment has been shown to be effective in patients with hetero-
geneous emphysema, but this treatment has not been 
exclusively investigated in homogeneous emphysema.  Ob-
jectives: The aim of this study was to investigate the safety 
and efficacy of LVR coil treatment in patients with homoge-
neous emphysema.  Methods: In this single-arm, open-label 
study, patients received a maximum of 12 LVR coils ( PneumRx 
Inc., Mountain View, Calif., USA) in each upper lobe in two 
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 Chronic obstructive pulmonary disease (COPD) is a 
major cause of chronic morbidity and mortality worldwide 
and it will become the third leading cause of death by 2020 
 [1] . COPD is characterized by a spectrum of small airway 
abnormalities (the ‘bronchitic’ component) and lung pa-
renchymal destruction (the ‘emphysema’ component). Pa-
renchymal destruction of the lung reduces the protective 
elastic recoil forces on the airways leading to increased air-
way collapsibility. This emphysema component may con-
tribute importantly to the airflow limitation due to the nar-
rowed and obliterated small airways in COPD  [2] . These 
combined pathophysiological effects may result over time 
in clinically important air trapping and hyperinflation. 
Lung hyperinflation correlates with important patient-re-
lated outcomes, such as dyspnea, exercise performance, 
physical activity and quality of life  [2] . In patients with se-
vere COPD, the currently available pharmacological treat-
ment options have only limited effectiveness. For patients 
with the emphysematous COPD phenotype, surgical and 
bronchoscopic therapeutic interventions exert an effect 
through reducing hyperinflation  [3] . However, until now 
only patients with severe emphysema and a heterogeneous 
distribution have been selected for surgical or broncho-
scopic interventions. The National Emphysema Treatment 
Trial showed that lung volume reduction (LVR) surgery 
improved quality of life, pulmonary function and exercise 
tolerance, especially in patients with predominant upper 
lobe emphysema  [4] . Over the past years a number of new 
minimally invasive bronchoscopic LVR modalities have 
been investigated, these being mainly effective in patients 
with heterogeneous emphysema. Endobronchial one-way 
valve placement has shown to be of benefit especially in a 
small subgroup of patients with heterogeneous emphyse-
ma  [5, 6] . Using a lung sealant for emphysema, upper lobe 
target sites have a greater treatment response in heteroge-
neous emphysema when compared to homogeneous dis-
ease  [7] . We recently showed that LVR coil treatment in 
patients with upper lobe heterogeneous emphysema im-
proved quality of life, hyperinflation and exercise capacity 
 [8] . One major randomized sham-controlled trial investi-
gating the use of bronchoscopic airway bypass, dedicated 
to patients with homogeneous emphysema, showed short-
term but no sustainable benefit  [9] . To date, there is no 
solid evidence for the efficacy of bronchoscopic LVR treat-
ment in patients with exclusively homogeneous emphyse-
ma defined by strict computed tomography (CT) criteria. 
Therefore, we investigated the safety and efficacy of LVR 
coil treatment in patients with homogeneous emphysema.
 Methods 
 Patients and Study Design 
 This study was a prospective, open-label, single-center cohort 
trial for patients with severe emphysema and a homogeneous dis-
tribution assessed on chest tomography. All patients were on op-
timal medication and completed a rehabilitation program. The 
main inclusion and exclusion criteria are shown in  table 1 . The 
protocol included a 6-month follow-up after the first treatment. 
This study was approved by the University Medical Center of 
Groningen medical ethics committee (NL36612.042.11). The trial 
is registered with ClinicalTrials.gov (No. NCT01421082). All study 
patients gave written informed consent.
 LVR Coils and the LVR Coil Procedure 
 The LVR coil is an implantable, shape-memory Nitinol de-
vice. The system (RePneu ® , Lung Volume Reduction Coil Sys-
tem, PneumRx Inc., Mountain View, Calif., USA) consists of a 
single-patient use delivery system with a cartridge, catheter, 
guide wire, forceps and coils ( fig. 1 ). These self-actuating coils 
are delivered via the bronchoscope into the airway in a straight 
configuration and recover to a non-straight pre-determined 
shape upon deployment. The coil is available in 3 lengths (100, 
125 and 150 mm) to accommodate different airway lengths. The 
distal and proximal ends of the coil are designed to reside in 
subsegmental airways. In this study, the bronchoscopy was 
 Table 1.  Study inclusion and exclusion criteria
Main inclusion criteria
– >35 years of age
– CT scan indicating homogeneous emphysema
– Post-bronchodilator FEV1 ≤35% predicted
– Post-bronchodilator FVC ≤90% predicted
– TLC >120% predicted
– RV >225% predicted
– RV/TLC >60%
– Dyspnea score >1 on mMRC scale of 0–4
– Stopped smoking for a minimum of 6 months prior to
procedure
– Signed informed consent
Main exclusion criteria
– DLCO <20% predicted
– History of recurrent clinically significant respiratory 
infection
– Uncontrolled pulmonary hypertension defined by right 
 ventricular pressure >50 mm Hg
– Inability to walk >140 m (150 yards) in 6 min
– Evidence of other disease that may compromise survival, such 
as lung cancer, etc.
– Clinically significant bronchiectasis
– Giant bullae >1/3 lung volume
– Previous LVR surgery, lung transplant or lobectomy
– >20 mg prednisone (or equivalent) daily
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 performed under general anesthesia using a 9.0-mm endotra-
cheal flexible tube and flexible bronchoscope (BF180; Olympus, 
Hamburg, Germany; 2.8-mm working channel, 6.0-mm outer 
diameter), and coil deployment was completed under fluoro-
scopic guidance. Following recovery from anesthesia, patients 
stayed in the hospital overnight for observation. The LVR coil 
procedure in this study was performed as described previously 
 [8] , with placement of a maximum of twelve LVR coils per up-
per lobe and by using a standardized segmental treatment algo-
rithm independent of specific CT findings. During the first pro-
cedure the coils were placed into the right upper lobe (RB2-RB1-
RB3) and 2 months later during the second procedure the coils 
were placed into the left upper lobe (LB1/2-LB3-LB4, leaving 
LB5 untreated because of its proximity to the heart). Patients 
received as per our standard interventional bronchoscopy pro-
phylactic regimen a 5-day course of prednisolone (25 mg once 
daily), starting 2 days before the procedure, and a 5-day course 
of azitromycin (250 mg once daily), starting on the procedure 
day.
 Follow-Up 
 Safety was assessed by recording all the adverse events that oc-
curred. Adverse events were divided into those occurring in the 
first 30 days after each LVR coil treatment, the period which we 
regarded to be related to the actual procedure (labeled as the re-
covery period), and those occurring in the 31 days between proce-
dure 1 and procedure 2, and the 31 days from procedure 2 to the 
6-month follow-up after procedure 1 (labeled as the follow-up pe-
riod). At baseline and the final 6-month follow-up we performed 
a high-resolution volume CT scan, measured quality of life using 
the St. George’s Respiratory Questionnaire (SGRQ)  [10] , assessed 
the health status of COPD patients using the Clinical COPD Ques-
tionnaire (CCQ)  [11] and measured the disability of our patients 
with the modified Medical Research Council dyspnea scale 
(mMRC)  [12] . We performed pulmonary function testing (spi-
rometry, body-plethysmography and diffusion capacity using a 
Jaeger MasterScreen TM Body Plethysmograph) and impulse oscil-
lometry according to the ATS/ERS guidelines  [13, 14]  and using 
reference values from workers of the European Community for 
Steel and Coal  [15] . The 6-min walking distance (6MWD) test was 
done according to ATS recommendations  [16] , and was prospec-
tively chosen as the primary endpoint. Besides the conventional 
body plethysmography pressure/volume loops, we also obtained 
resistance/volume graphs using an automated conversion pro-
gram (CareFusion Corporation)  [17] . The resistance/volume 
graph gives information about the combination of the within 
breath course of the dependency of absolute lung volume on air-
way resistance.
 CT Scan Qualifications and Analysis 
 The chest CT scan slice thickness was 1.0 mm, made at 120 
kV/210 mAs. All quantifications were performed with CIRRUS 
Lung 13.10 (http://cirrus.diagnijmegen.nl; Diagnostic Image 
Analysis Group, Nijmegen, The Netherlands; Fraunhofer MEVIS, 
Bremen, Germany)  [18–20] . The lungs and lobes were automati-
cally segmented and visually inspected. Emphysema severity was 
computed as an emphysema score, i.e. the percentage of voxels 
below –950 Hounsfield units, and this score was computed for the 
entire lung and per lung lobe. The airways were excluded to ensure 
that only lung parenchyma was analyzed. Patients were considered 
to be homogeneous and eligible when the difference in destruction 
between ipsilateral lobes was less than 15% using this analysis for 
both lungs.
 Statistics 
 Safety is reported descriptively. The other results are presented 
as medians and range. The Wilcoxon signed-rank test was used to 
assess the statistical significance of changes from baseline. A p val-
ue of <0.05 was considered statistically significant. IBM SPSS Sta-






 Fig. 1. Components of the RePneu Lung 
Volume Reduction Coil System. 
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 We screened 11 patients between November 2011 and 
July 2012. One patient was not eligible due to a residual 
volume (RV) percent predicted value of 195%. Ten pa-
tients were treated bilaterally in two sequential proce-
dures (see  table 2 for demographics and baseline charac-
teristics).
 The median emphysema CT destruction scores of the 
treated patients expressed as the percentage relative area 
of destruction below –950 Hounsfield units for the right 
lung were: upper lung 39% (range 34–51) and lower lung 
33% (range 26–53), and for the left lung were: upper lung 
37% (range 29–47) and lower lung 35% (range 24–49).
 LVR Coil Procedure 
 In 10 patients we performed 20 procedures in which a 
total of 227 LVR coils were placed, with a median of 11 
(range 10–12) coils positioned in 33 (range 22–55) min 
per lung. No periprocedural technical events occurred, 
and all coils were placed as planned. Of the 227 coils 
placed in this study, none had to be replaced or removed 
(see  table 3 for all procedural results). The median hospi-
tal stay after the procedure was 1 night (range 1–4).
 Safety 
 No adverse events occurred due to anesthesia in 
these patients with severe COPD. After the procedure, 
we observed only one small 2-cm apical pneumothorax 
which spontaneously resolved without a chest tube. No 
other serious adverse events occurred in the first 30 
days following each procedure (defined as the recovery 
period). During the follow-up period (31 days after 
procedure 1 to procedure 2, and 31 days after proce-
dure 2 to 6 months after procedure 1) two serious ad-
verse events were reported due to COPD exacerbations 
requiring hospitalization. All the adverse events in this 
study were managed with standard care and no life-
threatening events occurred. All adverse events are list-
ed in  table 4 .
 Efficacy 
 Comparing the 6-month follow-up results to baseline 
revealed that bilateral LVR coil treatment had resulted 
in a significant improvement in exercise performance as 
measured by an increase in 6MWD from 289 to 350 m 
(p = 0.005). Quality of life also showed significant im-
provements as measured by a change in SGRQ total 
score from 63 to 48 points (p = 0.028) and by a change 
in CCQ score from 3.0 to 2.3 points (p = 0.007). There 
was also a significant improvement in lung volumes, 
with forced vital capacity (FVC) improving from 2.17 to 
2.55 liters (p = 0.047) and RV from 5.04 to 4.44 liters (p = 
0.007). Airway resistance (Raw) changed significantly 
with a decrease in Raw from 0.82 to 0.62 kPa/l/s (p = 
0.009). CT scan analysis showed a significant decrease in 
lung volume in the treated upper lobes from 3,204 to 
2,941 ml (p = 0.037), while in non-treated lower lobes 
there was no change in lung volumes (3,496–3,489 ml, 
 Table 2.  Patient demographics and baseline characteristics (n = 10)
Age, years 54 (44–66)
Female/male 9/1
Pack years, n 40 (25–60)
BMI, kg/m2 22.4 (16.2–28.7)
FEV1, % predicted 22 (19–31)
FVC, % predicted 69 (52–89)
FEV1/FVC, % 29 (19–38)
TLC, % predicted 141 (121–182)
RV, % predicted 253 (217–375)
RV/TLC 0.68 (0.61–0.74)
Raw, % predicted 272 (180–403)
DLCO, % predicted 31 (23–42)
PaCO2, kPa 5.9 (4.4–6.9)
PaO2, kPa 9.2 (7.3–10.6)
Patients on home oxygen, n 6
6MWD, m 289 (160–485)
mMRC 2.5 (2–4)
SGRQ total score 63 (45–79)
CCQ 3.0 (1.9–3.8)
 Values in parentheses are the range. FEV1 = Forced expiratoiry 
volume in 1  s; DLCO  = carbon monoxide diffusion capacity; 
PaCO2 = arterial carbon dioxide pressure; PaO2 = arterial oxygen 
pressure.
 Table 3.  LVR coil procedural results
Procedures, n 20
Procedure time, min 33 (22–55)
Post-procedure hospital stay, days 1 (1–4)
Coils per procedure, n 11 (10–12)
Total coils implanted 227
Upper right lobe 113
Upper left lobe 114




Values in parentheses are the range.
 Klooster/ten Hacken/Franz/Kerstjens/
van Rikxoort/Slebos 
 Respiration 2014;88:116–125 
DOI: 10.1159/000362522
120
p = 0.646). All baseline and 6-month follow-up results 
are shown in  table 5 .
 Seventy percent of the patients responded by more 
than the minimal clinically important difference (MCID) 
for 6MWD, RV  [21] , SGRQ  [22]  and CCQ  [11] ( table 6 ). 
Individual patient data at baseline and follow-up for 
6MWD, SGRQ, RV and Raw are shown in  figure 2 .
 Discussion 
 In this trial we demonstrated for the first time pro-
spectively the feasibility and safety of LVR coil treat-
ment specifically in patients with severe COPD and ho-
mogeneous emphysema. Despite the small sample size 
of this study, LVR coil treatment significantly improved 
hyperinflation, exercise tolerance and quality of life, 
with 70% of the patients responding by at least the 
MCID.
 In this severely diseased group of patients it was safe to 
perform the LVR coil procedure under general anesthe-
sia. To minimize the anesthesiology time and reduce the 
risk of bilateral procedure-induced complications, we 
performed the LVR coil treatment in two consecutive 
procedures 8 weeks apart. No anesthesia-related events 
occurred. The adverse events profile seen with the LVR 
coil treatment appears acceptable as only one small apical 
pneumothorax not needing chest tube drainage occurred 
directly after the procedure, whereas two COPD exacer-
bations were recorded as serious adverse event during the 
follow-up. Beforehand, one would expect extra coughing 
and sputum production after implanting more than 20 
coils in diseased airways. However, the symptoms score 
assessed with the SGRQ demonstrated a significant re-
duction.
 In patients with severe emphysema, only patients with 
a heterogeneous disease distribution have so far been seen 
as the proper candidates for effective treatment by both 
LVR surgery  [4] and a number of bronchoscopic LVR 
modalities, such as endobronchial one-way valve place-
ment  [5] , thermal vapor ablation  [23]  and using lung seal-
ant  [24] . In patients with homogeneous emphysema all 
these procedures showed limited efficacy.
 The first clinical pilot LVR coil study, using a maxi-
mum of 6 coils per lobe, suggested that patients with ho-
mogeneous emphysema might not benefit as well as pa-
tients with heterogeneous emphysema  [25] . In the second 
LVR coil study only patients with heterogeneous emphy-
sema were included and treated with a new generation 
coil, with the number of coils implanted in the lobe in-
creased  [8] . In our study we now show a high responder 
efficacy rate in patients with homogeneous emphysema. 
These results are also supported by recently published 
randomized controlled trial data (RESET trial) where 
both heterogeneous as well as homogeneous emphysema 
patients had improved quality of life, exercise tolerance 
and hyperinflation at 3 months after LVR coil treatment 
compared to controls  [26] . Future prospective random-
ized controlled trial data will have to confirm our find-
ings. Currently, two larger (n = 315 and n = 100) random-
ized controlled trials using LVR coils in both heteroge-
neous and homogeneous populations are underway 
(NCT01608490 and NCT01822795).
 In our study, we observed a significant decrease in air-
way resistance as measured by body plethysmography 
and by forced oscillation after bilateral LVR coil treat-
ment. Beforehand, one might expect that implantation of 
coils inside the airways would obstruct airflow and in-
crease airway resistance. Apparently, the mechanical 
properties of the lung are improved by the treatment and, 
importantly, our study also suggests that the lung paren-
chyma in subjects with homogeneous emphysema is 
healthy enough to transfer the elastic recoil forces to the 
airways. The effects of our coil treatment on airway pa-
tency were substantial since we found significant im-











Respiratory failure 0 0
Death 0 0
Adverse events
Slight hemoptysis (<5 ml) 5 0
Chest discomfort (non-cardiac) 6 0





 The recovery period is defined ≤30 days after each LVR-coil 
procedure. The follow-up period is defined as 31 days post-proce-
dure 1 to pre-procedure 2, and 31 days post-procedure 2 to the 
6-month follow-up after procedure 1.
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provements in airway resistance, despite the fact that im-
proved residual volumes lead to reduced airway patency 
and, thus, underestimation of improved airway resis-
tance. To illustrate this we took the example of 2 patients 
before and after treatment ( fig. 3 ) and plotted ‘resistance/
volume’ graphs. The interpretation of body-plethysmog-
raphy measurement is traditionally based on the results 
of the lung volumes and the airway resistance. The graph-
ic presentation of the airway resistance is normally dis-
played as pressure/volume loops. Important intra-breath 
information incorporating inhomogeneity of ventilation, 
expiratory flow limitation or airways closure is not pre-
sented in this form. When combining the ‘traditional’ air-
ways resistance (Raw) loop and the intra-thoracic gas vol-
ume (ITGV) graphs, the resistance/volume graph can be 
determined. The maneuver of the body-plethysmograph-
ic measurement is not changed and there are no addi-
tional efforts or maneuvers necessary for the patient. The 
resistance/volume graph just gives additional informa-
tion about the volume-dependent airway resistance dur-
 Table 5.  Baseline and 6-month follow-up results (20 bilateral LVR coil treatments in 10 patients)
Baseline 6-Month follow-up p value
6MWD, m 289 (160–485) 350 (192–520) 0.005
FEV1, l 0.58 (0.45–0.93) 0.69 (0.56–1.02) 0.102
FVC, l 2.17 (1.82–3.17) 2.55 (1.81–3.67) 0.047
ITGV, l 6.02 (5.28–7.19) 5.84 (4.63–7.13) 0.009
TLC, l 7.48 (6.46–9.08) 7.36 (5.97–9.09) 0.037
RV, l 5.04 (4.14–6.57) 4.44 (3.57–5.68) 0.007
RV, % predicted 253 (217–375) 231 (172–325) 0.007
RV/TLC, % 68 (61–74) 60 (55–67) 0.005
Raw, kPa/l/s 0.82 (0.54–1.21) 0.62 (0.43–0.91) 0.009
R5-R20, kPa/l/s 0.28 (0.21–0.64) 0.27 (0.14–0.44) 0.043
SGRQ total, points 63 (45–79) 48 (25–68) 0.028
SGRQ symptoms, points 63 (13–79) 36 (2–69) 0.017
SGRQ activity, points 89 (72–100) 79 (35–93) 0.018
SGRQ impacts, points 44 (16–71) 32 (14–64) 0.074
CCQ, points 3.0 (1.9–3.8) 2.3 (1.4–3.0) 0.007
mMRC, points 2.5 (2–4) 2.0 (1–4) 0.16
CT volume RUL, ml 1,514 (1,096–1,700) 1,399 (1,126–1,702) 0.053
CT volume LUL, ml 1,685 (1,157–1,901) 1,547 (1,218–1,868) 0.037
CT volume treated lobes, ml 3,204 (2,253–3,601) 2,941 (2,344–3,570) 0.037
CT volume untreated lobes, ml 3,496 (2,172–4,262) 3,489 (2,071–4,244) 0.646
 Median values are presented with range in parentheses. FEV1 = Forced expiratory volume in 1 s; R5 = airway 
resistance at 5 Hz; R20 = proximal resistance at 20 Hz; RUL = right upper lobe; LUL = left upper lobe.
 Table 6.  Responder rates at 6 months after LVR coil treatment using MCID for RV, 6MWD, SGRQ and 
CCQ
Variable MCID Reference Responder rate at 
6 months, %
RV ≥0.43 liters [21] 70 
6MWD ≥26 m [29, 30] 70 
6MWD ≥48 m [31] 50 
SGRQ ≥4 points [22] 70 
SGRQ ≥8 points 70 
CCQ ≥0.4 points [11] 80 
 Values are given as the percentage of patients responding.
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Median value (p = 0.028)
Patient B
Patient A
 Fig. 2. Individual patient data at baseline and at 6-month follow-up (FU) for 6MWD, SGRQ, RV and Raw (pa-
tients A and B are shown in more detail in figure 3). 
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ing a breathing cycle, and can be very useful for any dif-
ferences before and after treatment. Nevertheless, the 
mechanisms of action of the LVR coil are not fully under-
stood and additional studies are needed to learn more 
about the lung compliance, elastic recoil and diaphragm 
function before and after LVR coil treatment.
 Total lung capacity (TLC) was both measured by body-
plethysmography as well as inspiratory high-resolution 
CT scans (HRCT). TLC measured by body-plethysmog-
raphy appeared to be higher compared to TLC measured 
by HRCT. However, the decrease in TLC at the 6-month 
follow-up using HRCT analysis appears to be greater than 
the TLC measured by body-plethysmography.
 It is difficult to explain these subtle differences. It is 
known in COPD patients that TLC can be up to 2 liters 
greater than the TLC measured by HRCT, especially in 
patients with severe COPD  [27] . Also, the measurement 
of TLC by body-plethysmography is not without errors, 
particularly in severe COPD, and the same applies to TLC 
measurement by HRCT.
 A limitation of our cohort study is that the design can-
not correct for potential placebo effects, which is especial-
ly important for the questionnaire data (SGRQ, mMRC 
and CCQ). However, in other published uncontrolled 
LVR device trials using a bilateral intra-bronchial valve 
placement in patients with severe emphysema, no signifi-
cant changes were observed in 6MWD or pulmonary 
function parameters despite this bronchoscopic treatment 
 [28] . Also, the EASE trial data showed no placebo effect 
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 Fig. 3. Pressure/volume loops and resistance/volume graphs of 2 
patients as an illustrative example of changing lung mechanical 
properties at baseline and 6 months after LVR coil treatment. The 
resistance/volume graph presents the single breath course of air-
way resistance, dependent on absolute lung volume. VT = Tidal 
volume (liters); FRC = functional reserve volume (liters); ERV = 
expiratory reserve volume (liters). 
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of life questionnaires in a randomized sham-controlled 
intervention trial design using the airway bypass approach 
 [9] . Although a contribution from a placebo effect cannot 
be excluded, in our opinion the magnitude of the current 
effect size exceeds any potential placebo effect.
 In conclusion, LVR coil treatment in patients with ho-
mogeneous emphysema is a promising bronchoscopic 
technique. The procedure is safe and feasible. There is a high 
responder rate and patients have demonstrated clinically 
meaningful improvements in exercise capacity, pulmonary 
function and quality of life at 6 months of follow-up.
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